Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 26, 2024
Deals
Sarepta broadens pipeline via siRNA deal with Arrowhead, paying $825M up front
CEO Ingram sees “the one significant strategic transaction” to transform Sarepta’s future, while Arrowhead preps for first-ever launch
BioCentury | Aug 14, 2024
Product Development
Clinical Report: Acelyrin shifts priorities; Rivus moving forward in obesity
Plus: Readouts from Avidity, Apellis/Sobi, Levicept and Merck
BioCentury | Jul 18, 2024
Finance
Venture Report: Five biotechs raise nearly $800M in two-day flurry
Plus: New capital for CytoReason, Truvian and Renalys
BioCentury | Apr 30, 2024
Data Byte
EMA’s CHMP recommends Takeda VEGF therapy, Idorsia hypertension drug
April opinions also include earlier-line use of J&J’s Rybrevant and BMS’s Opdivo
BioCentury | Mar 23, 2024
Data Byte
EMA’s CHMP backs approval of Novartis’ complement drug
March decisions also include label extensions for UCB’s Bimzelx and Astellas’ Xtandi. Takeda pulls an application for Adcetris
BioCentury | Mar 14, 2024
Deals
AstraZeneca’s Amolyt takeout among largest ever for a French biotech
Deal for $800M up front adds hypoparathyroidism asset, now in Phase III, to AZ’s Alexion portfolio; shareholders could receive $250M milestone
BioCentury | Jan 27, 2024
Data Byte
EMA’s CHMP confirms non-renewal of Translarna, denies new medicines Nezglyal and Syfovre
On the positive side of the ledger, BMS’s CAR T therapy Abecma headed for a line extension
BioCentury | Dec 12, 2023
Deals
Dec. 11 Quick Takes: BMS paying $800M up front for SystImmune’s bispecific ADC
Plus: Pain, hearing loss company Hoba raises €23M and more from Novartis, Cogent and Zafrens
BioCentury | Dec 7, 2023
Politics, Policy & Law
Dec. 6 Quick Takes: Pfizer CEO excoriates university presidents on antisemitism failure
Plus: J&J’s Duato: GLP-1 space ‘too crowded’ to enter, Pfizer leaving BIO and updates from Merck KGaA, Pharvaris, Novartis, Arvinas, Seagen, EyePoint and CatalYm
Items per page:
1 - 10 of 291